Comparison of the Acute Hematopoietic Capacities of Erythropoietin and U-74389G Concerning Hematocrit Levels

Author(s): Constantinos Tsompos*, Constantinos Panoulis, Konstantinos Toutouzas, Aggeliki Triantafyllou, George Zografos, Apostolos Papalois.

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 17 , Issue 1 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Aim: This study compared the hematopoietic capacities of erythropoietin (Epo) and antioxidant drug U-74389G, based on 2 preliminary studies. The provided results on hematocrit levels augmentation were co-evaluated in a hypoxia reoxygenation protocol of an animal model.

Materials and Methods: Hematocrit levels were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G.

Results: The first preliminary study of Epo non-significantly increased the hematocrit levels by 0.24%+1.38% (p-value=0.8586). The second preliminary study of U-74389G significantly raised the hematocrit levels by 3.16%+1.33% (p-value=0.0196). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has approximately 12.66-fold higher hematopoietic potency than Epo (p-value=0.0000).

Conclusion: The anti-oxidant capacities of U-74389G provide satisfactory acute hematopoietic properties; presenting approximately 12.66-fold hematocrit level rise than epo (p-value=0.0000).

Keywords: Hypoxia, erythropoietin, U-74389G, hematocrit levels, reoxygenation, cytokine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [24 - 27]
Pages: 4
DOI: 10.2174/1871529X17666170201104158
Price: $58

Article Metrics

PDF: 15